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Background: We aimed to investigate the use of ovarian cyst fluid as a source for biomarker discovery and to find
novel biomarkers for use in the diagnosis of epithelial ovarian tumors.
Results: Ovarian cyst fluids from 218 women were collected and 192 (benign n = 129, malignant n = 63) were
analyzed using mass spectrometry. 1180 peaks were detected, 221 of which were differently expressed between
benign and malignant ovarian tumors. Seventeen peaks had receiver operating curve and area under the curve
values >0.70; the majority of these represented peaks for apolipoproteins C-III and C-I (ApoC-I), transthyretin (TTR),
serum amyloid A4 (SAA4), and protein C inhibitor (PCI). ApoC-III, PCI, and serum CA125, with an ROC AUC 0.94 was
the best combination for diagnosing epithelial ovarian cancer. ApoC-III and PCI was analyzed with ELISA in the
original cohort (n = 40) and in 40 new cyst fluid samples for confirmation with an independent method and
validation. Results from MS and ELISA for ApoC-III correlated well (p = 0.04). In the validation set, ApoC-III was
significantly (p = 0.001) increased in the malignant epithelial ovarian cancers.
Conclusions: Fluid from ovarian cysts connected directly to the primary tumor harbor many possible new
tumor-specific biomarkers. Biomarkers found in ovarian cyst fluid may be used as molecular imaging targets for
early diagnostics and prediction of therapy. Plasma abundant proteins are also influencing the cystic fluid
proteome. Methods for isolating less frequent cyst fluid proteins are needed.
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The incidence of ovarian cancer in Europe and the United
States is 11/100 000, and about 200 000 women world-
wide are diagnosed with the disease each year [1]. More
than 70% of all ovarian cancers are detected in the late
stages (FIGO III-IV), and the five-year survival rate is
only 25–30% for these patients. If, however, ovarian
cancer is detected in stage I, when the disease is still
confined to the ovary, the five-year survival rate is over
85% [2]. Neither reliable diagnostic tests nor accurate
imaging techniques are yet available to distinguish be-
tween benign and malignant cysts. Improvement in the
diagnosis of this lethal disease is very desirable. Serum
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distribution, and reproduction in any mediumand HE4 have shown promising results in women with a
pelvic mass [3,4], but CA125 shows false negative results
in approximately 40% of stage I tumors [5]. HE4 comple-
ments CA125 especially in younger women, were CA125
can be false positive in a variety of physiological condi-
tions and benign diseases, including endometriosis [6].
These markers are not sensitive enough for the reliable
detection of small volume disease, and complementation
with other markers is required.
Over the past twenty years, different strategies have
been applied to search for new biomarkers as diagnostic
tools for the early detection of EOC. One approach is
genomics with RNA expression array-based research;
others focus on proteins using MS and ELISA [7]. Serum
is the most common source in the search for new bio-
markers, but proteomic profiles of urine and ascites have
also been evaluated [8-11]. Because the blood proteome
contains contributions from all organ systems in the
body, an alternative approach is the proteomic analysisentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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breast- or pancreatic cancer, and in our case cyst fluids
from the ovary [12]. Ovarian tumors commonly grow in
cystic formations, regardless of histology. A cyst can be-
come large enough to reach the diaphragm and still be
benign, while a stage III cancer with ascites and periton-
eal carcinomatosis may present with relatively small
changes in the ovaries. The ovarian cyst fluid probably
represents the local microenvironment, containing pro-
teins secreted directly by ovarian tumor cells, surround-
ing stroma and other cells involved in the tumorigenesis.
Early pathological changes within this organ may there-
fore be reflected in proteomic patterns found in ovarian
cyst fluid before secretion into the blood stream. If so,
biomarkers in the cyst fluid may be used as direct tar-
gets for new diagnostic imaging techniques in early stage
ovarian cancer. Few discoveries of markers for diagnos-
tics and prognosis have been reported in studies of ovar-
ian cyst fluid [13-16], but ovarian cysts, especially those
that are malignant, have higher concentrations of pro-
teins than diluted serum and urine [15].
In this study, we collected 218 cyst fluid samples, 192
were diagnosed with benign, borderline type, and malig-
nant ovarian tumors of different histology and stages
and analyzed with SELDI-TOF MS. Five most significant
peaks were identified and a peak combination with high-
est ROC AUC was evaluated. ELISA was used to con-
firm and validate protein expression found by SELDI-Table 1 Significantly (p<0.0001) different mass peaks betwee
>0.70 are listed with m/z value and identified peaks








ApoC-I - truncated MEP-M1 6448





Hb beta FT 8037
Albumin FT 54622
Albumin FT 54426
Albumin ion MEP-M1 44754
PCI = protein C inhibitor, ApoC-III = apolipoprotein C-III, ApoC-I = apolipoprotein C-I,
differentially eluted yield fractions E2, and E3, MEP =Mercapto ethyl pyridine beadsTOF MS in the original sample set and a new set of cyst
fluids. CA125 was analyzed in corresponding serum
samples from our original cohort and used in the ROC
AUC calculations. Our aim was to analyze the prospect




Seventeen significant peaks had ROC AUC values >0.70
A total of 1180 peaks were resolved by SELDI-TOF
MS, and of these, 221 peaks were differently expressed
(p <0.0001) in benign and malignant samples. Several
peaks in the cyst fluid were identified as albumin and other
proteins that also are abundant in blood [17]. Seventeen
peaks had ROC AUC values of >0.70 when comparing be-
nign and malignant cases (Table 1). Of these 17 peaks, 5
peaks were identified as apoliprotein C-III (ApoC-III), 3
peaks as apolipoprotein C-I (ApoC-I), 2 peaks as trans-
thyretin (TTR), 1 peak as serum amyloid A4 (SAA4), and
1 peak as protein C inhibitor (PCI; SerpinA5) (see meth-
ods section). A comparison of peak levels in fluid from
benign and borderline cysts showed no significant dif-
ferences for any of the five peaks. Due to the small
group size borderline tumors (n = 16), were not further
evaluated, but their peak levels are shown in the scat-
ter plots for each protein (Figure 1A-E). The study
population was between 16–86 years old, median agen benign and malignant cyst fluid samples, with ROC AUC
ntensity benign/malignant ROC AUC Specificity % (CI)
30.23 / 7.00 0.79 67.7 (58.9-75.6)
3.60 / 15.09 0.82 68.5 (59.7-76.3)
5.29 / 22.00 0.80 60.8 (51.8-69.2)
4.65 / 24.2 0.80 60.8 (51.8-69.2)
3.20 / 14.7 0.79 63.1 (54.2-71.4)
7.30 / 33.20 0.78 50 (41.1-58.9)
37.53 / 121.14 0.78 57.7 (48.7-66.3)
68.91 / 184.53 0.76 53.1 (44.1-61.9)
24.49 / 52.75 0.76 53.1 (44.1-61.9)
1.35 / 2.42 0.76 58.5 (49.5-67.0)
1.53 / 2.72 0.74 59.2 (50.3-67.8)
7.80 / 23.16 0.77 59.2 (50.3-67.8)
5.36 / 14.27 0.75 57.7 (48.7-66.3)
2.61 / 4.64 0.75 65.4 (56.5-73.5)
0.73 / 0.30 0.76 61.5 (52.6-69.9)
1.72 / 0.25 0.75 60.8 (51.8-69.2)
1.06 / 0.50 0.76 57.7 (48.7-66.3)
SAA4 = serum amyloid A4, and TTR = transthyretin, EB = Equalizer Beads,
, differentially eluted yield fractions M1.
Figure 1 Peak intensity in cyst fluids from benign, borderline type, and malignant ovarian tumors (n = 192). (A) ApoC-III; (B) ApoC-I;
(C) SAA4; (D) TTR; (E) PCI.
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same as for the malignant cohort (Table 2). Analysis of
peak levels correlation with age showed that protein
levels were not influenced by patients’ age (data not
shown). There was high percentage of stage I + II
(50%) in the original population of women with ovar-
ian cysts (Table 2).Table 2 Sample characteristics of the original cohort includin
excluded samples, n = 26)
Total Benign Borderline Malignant
n = 192 n = 129 n = 16 n = 47 I n = 21
Mean Age (range) 60 (16-86) 56 (40-85) 61 (40-85)






Serous 45 (35) 9 (56) 30 (64) 11
Mucinous 25 (19) 7 (44) 6 (13) 4
Endometrioid 5 (11) 4
Clear cell 3 (6) 1
Undifferentiated 3 (6) 1Peaks for Apo C-III and PCI in combination - independent
predictor of malignancy
The peaks with highest ROC AUC for each protein in
cyst fluid (PCI, ApoC-III, ApoC-I, SAA4 and TTR) were
selected for further statistical analysis together with cor-
responding serum CA125. ROC AUC for serum CA125
was 0.87 (CI 0.80-0.94). Combined ROC AUC for theg age, histology, stage (FIGO), and grade (without
Stage Grade
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Figure 2 (A) Scatter plot of logarithmic values of the two independent markers, ApoC-III and PCI; (B) ROC AUC of CA125 only and of
CA125 combined with ApoC-III and PCI.
Table 3 Characteristics of the samples from the original
cohort and new samples including histology and stage
(FIGO), used in the ELISA confirmation and validation of
SELDI-TOF MS results
Benign Stage I Stage II Stage III Malignant
Original cohort: n = 20: n = 12: n = 0: n = 8: n = 20:




Serous 8:8 6:2 0:1 6:11 12:14
Mucinous 5:4 3:1 1:0 4:1
Endometrioid 2:2 2:2
Clear cell 1:2 1:0 2:2
Undifferentiated 0:1 0:1
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regression analyze showed that peaks for ApoC-III
(p <0.0001) and PCI (p = 0.001) were independent factors
in predicting malignancy (Figure 2A). These two markers
together achieved ROC AUC of 0.91 (CI 0.85-0.96), the
same as for the 5 markers ROC AUC. Marker panel of the
peaks for ApoC-III, PCI, and serum CA125 generated the
highest ROC AUC of 0.94 (CI 0.89-0.98) (Figure 2B). The
specificity of this three-marker panel was 88.4% compared
to 68.2% for CA125 alone. CA125 showed a sensitivity of
81.8% using cut-off 35 U/ml, accordingly specificity was
calculated for the peaks with highest ROC AUC at fixed
sensitivity of 81.8%; 68.5% and 67.7% for Apo-CIII and
PCI respectively (Table 1). None of the peaks showed su-
perior specificity to that of CA125 when analyzed alone.
Confirmation and validation - ELISA
This study was primarily conducted to explore ovarian
cyst fluid as a possible source of new biomarkers for de-
tection and diagnosis of ovarian cancer. With SELDI-
TOF MS we found 221 peaks to be differently expressed
between benign and malignant ovarian cyst fluid. How-
ever the suggested proteins for the peaks with best mar-
ker combination was chosen for confirmation of method
and validation in an external sample set.
Peaks for ApoC-III and PCI, which had the highest
ROC AUC in the MS analysis, were analyzed with ELISA
in 40 ovarian cyst fluid samples (Table 3) from the ori-
ginal cohort to evaluate their existence with an independ-
ent method. Results from the two different methods,
SELDI-TOF MS and ELISA, correlated for ApoC-III,
Spearman’s rho = 0.328; p = 0.04 (Figure 3A). Significant
(p < 0.05) increase of ApoC-III (ELISA) in the malig-
nant compared to the benign ovarian cysts was also
found (Table 4). PCI, however, was increased (ELISA)in the malignant ovarian cysts and decreased in the MS
analyze, which did obviously not correlate, (Spearman’s
rho -0.255; p = 0.11) (Figure 3B). The increase of PCI in
malignant compared to benign ovarian cyst fluids was
not significant (Table 4). Next, we analyzed a new set of
40 consecutively collected ovarian cyst fluid samples
(Table 3) for ApoC-III and PCI protein levels with
ELISA (Table 4). Median ApoC-III was 3.3 in benign
compared to 22.7 in malignant ovarian cyst fluids,
which was found to be significant (p = 0.001). Median
PCI (active antigen) was 4.7 in benign and 14.9 in
malignant ovarian cyst fluids, which was not significant
(p = 0.26).
Discussion
The aim of the present study was to analyze the pro-
spect of cyst fluid as a source for biomarker discovery.
A B
Figure 3 Scatter plot of correlations between SELDI-TOF MS (peaks) and ELISA (proteins) for the identified (A) ApoC-III (Spearman’s
rho 0,338; p = 0.04) but not (B) PCI (Spearmans’s rho -0.255; p = 0.11).
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peaks in our samples, showing that proteomic analysis
of ovarian cyst fluids may serve as a valuable tool in the
ongoing quest for new ovarian cancer biomarkers. Bio-
markers produced by the tumor are most likely to be
found close to the tumor in the initial phase, before ex-
cretion into the blood [12]. The existence of a protein in
cyst fluid can, however, also depend on diffusion from
the blood stream. The peaks with highest ROC AUC
separating benign from malignant ovarian cyst corre-
sponded to proteins that are also present in blood [17].
Even if some of these proteins are not directly expressed
by the tumors, they may reflect reactions that are closely
related to carcinogenesis, such as increased thrombotic
activity and inflammation, and may thus still be candi-
dates as markers for tumor detection.
MS techniques allow rapid and high throughput ana-
lysis of the entire proteome in a small biological sample.
One disadvantage with large scale screening methods
using serum samples is the dominance of highly abun-






APOC3 5.16 13.1 p < 0.
(0.2-52.8) (0.6-51.7)
PCI 52.8 100.4 NS
(17.5-177.7) (20.0-691.8)of only 20 abundant proteins i.e. albumin, immunoglo-
bulins, transferrin and macroglobulins [18]. By using
ovarian cystic fluid we made the assumption that we
would increase the chance for detection of rare, more
tumor-specific proteins. However, there seem to be a
high resemblance between ovarian cyst fluid and the
serum proteome since the abundant large proteins were
the most prominent ones also in the present study. Simi-
lar resemblances between serum and fluids from other
compartments such as pancreatic cysts, ascites and
breast duct fluids have also been described [8,11,12]. Use
of careful and selective depletion of high abundance pro-
teins from the ovarian cyst fluid might increase access to
other specific biomarkers. One major limitation with the
method used in the present study is the lack of exact
protein identification of the mass-peaks. Fortunately the
abundant peaks observed as differentially expressed be-
tween benign and malignant ovarian cystic fluid, have
been purified and confidently identified in several earlier
studies [19-27]. Especially the peaks for ApoC-I and
TTR have been correctly identified after several differentthod (ELISA) of MS peaks with the highest ROC AUC
Validation set
. Benign Malignant Sign.
Median Median
(range) (range)
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cyst fluids as a source for biomarker discovery of rare
but specific proteins, depletion must be performed and a
MS with accurate protein identification i.e isobaric tags
for relative and absolute quantification (iTRAQ) could
be used.
We compared the protein peak profiles in cysts from
benign and malignant ovarian tumors and detected
peaks corresponding to five potential biomarkers. In
combination with serum CA125, two mass peaks were
found to be predictors of malignancy (ROC AUC 0.94).
The first peak with the suggested protein, ApoC-III, is a
very low-density lipoprotein, a carrier protein for diverse
proteins, mainly synthesized in the liver and small intes-
tines. ApoC-III inhibits lipoprotein lipase and hepatic
lipase and plays an important role in regulating the tri-
glyceride rich lipoproteins and thereof regulates many
cellular functions. Our study is the first to describe
increased ApoC-III in ovarian cyst fluids. In the analysis
of an eleven protein panel in serum from patients with
ovarian cancer, increased Apo-CIII was one of the mar-
kers that could distinguish women with cancer from
those with benign conditions [28]. The second peak with
the suggested protein, PCI (SerpinA5), is a component
of the anticoagulant protein C pathway, originally identi-
fied in human plasma as an inhibitor of activated protein
C. PCI also inhibits urinary plasminogen activator (uPA),
which is a mediatior of tumor cell invasion [29]. PCI is
expressed in various human fluids and tissues but has
not previously been described in ovarian cyst fluids. Gene
and protein expression analysis revealed SERPINA5, the
gene encoding PCI, as down-regulated in serous ovarian
carcinomas compared with serous borderline tumors,
which is consistent with our MS results [30,31]. SER-
PINA5 expression is decreased in renal and prostate can-
cer and elevated levels have been related to better survival
in breast cancer [29,32,33]. However, although we found a
significant decrease of PCI levels in the malignant com-
pared to the benign cohort using SELDI-TOF MS we
could not confirm our MS results with an independent
method, ELISA. This suggests that the peak we identified
as PCI were incorrect identified. However, due to the
various functions and versatility of PCI it is challenging to
investigate PCI protein expression in body fluids [34]. In
blood PCI is found in various forms including inactive,
cleaved, and complex-bound. PCI is also modified through
post-translational events and has been reported as micro-
heterogeneous as a result of differences in N-glycan struc-
tures [35].
The other three peaks with ROC AUC > 70 identified
with mass matching from the literature in this study was
TTR, SAA4 and ApoC-I. TTR formerly called prealbumin,
has previously been identified as a potential early diagnos-
tic marker for ovarian cancer and known as a marker foracute-phase inflammatory response and nutritional status
[22,24]. A study of ovarian tumors showed a direct correl-
ation between serum levels, intracellular expression of
SAA4 and malignant state of the epithelial cells [36]. In
colon cancer SAA4 levels increases gradually from epithe-
lial dysplasia to cancer in tissue samples and are highest in
metastatic cancer, which supports the possibility of its role
in carcinogenesis [37]. In our study, SAA4 was up-
regulated in ovarian cyst fluid from patients with malignant
tumors, which is consistent with validated SELDI-TOF MS
in serum from ovarian cancer patients [26]. The peak for
ApoC-I was also increased in the malignant ovarian cysts
in our study. Takano et al. [38] have shown that ApoC-I is
abundantly expressed in pancreatic neoplastic epithelium.
It was also detected in the culture medium of a pancreatic
cancer cell line, which suggests that cancer cells secrete
ApoC-I. The elevated levels of ApoC-I in our analysis may
also depend on secretion of the protein from tumor cells.
The ultimate goal is to find superior biomarkers to those
already known to detect early EOC. Our group and others
evaluated CA125 and HE4 in blood from patients with
pelvic tumors. In the study by Moore et al. the ROC AUC
for CA125 was 0.83 compared to our 0.87 and in combin-
ation CA125 with HE4 0.91 and 0.85 respectively [3,4].
Bearing in mind that the selected peaks in this study has
not been analyzed for exact peptide sequence we still
choose to perform a comparative estimation of ROC AUC
between the benign and malignant samples. None of the
protein peaks detected in our study showed a better speci-
ficity than CA125 when considered in isolation. However,
a combination of the peaks for ApoC-III, PCI, and CA125
improved the ROC AUC significantly. The currently pre-
sented marker combination of serum CA125 and two cys-
tic fluid mass-peaks (ROC AUC 0.94) was comparable to
the above-mentioned algorithms [3,4]. Despite the draw-
backs of the method used in our present study, our results
strengthen our hypothesis that it is possible to find new
biomarkers in the ovarian cystic fluid that can diagnose
early ovarian cancer.
Conclusion
We demonstrate for the first time that ovarian tumor
cyst fluid is a promising source for the detection of novel
diagnostic biomarkers with proteomic profiling. Fluid
from ovarian cysts connected directly to the primary
tumor harbor many possible new tumor-specific biomar-
kers. Biomarkers found in ovarian cyst fluid may be used




Cyst fluids were collected prospectively and consecu-
tively from 218 women presenting with a suspected
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2001 to September 2006 (Table 2). Patients were diag-
nosed by transvaginal sonography or computed tomog-
raphy and admitted for surgical removal of the cyst by
skilled gynecologic oncology surgeons at Sahlgrenska
University Hospital, Gothenburg, Sweden. According to
our protocol, blood samples were taken after anesthesia
but before surgery, and ovarian cyst fluids were collected
after removal of the cyst from the abdomen. All samples
were immediately put in 4°C for 15-30 minutes, centri-
fuged, and aliquoted into Eppendorf tubes. The fluids
were transferred to −80°C, within 30–60 minutes after
collection. Samples used in this study had one freeze-
thaw cycle.
Sample characteristics
Of the 218 women originally included in the study, we
were unable to analyze nine samples due to their high
viscosity and high blood content. These nine samples
consisted of four benign lesions, one borderline type
tumor; FIGO stage IA, two serous EOC; FIGO stage IA
and IIIB and two endometrioid EOC; FIGO stage IIA
and IIIC. Three non-epithelial germ cell ovarian cancers
and fourteen samples that were found to be metastases
from cancers other than EOC were also excluded. CA125
was measured in blood samples from all patients with
ovarian disease using ELSA-CA125 (Cisbio Bioassays,
France) according to the manufacturer’s instructions. All
tumors were examined by an experienced pathologist for
diagnosis, histology, and grade (Table 2). The tumors were
staged (I-IV) according to FIGO standards (Table 2). The
study was approved by the local ethics committee at the
University of Gothenburg, and each patient provided their
informed written consent.
Protein expression profiling of ovarian cyst fluid – SELDI-
TOF MS
High throughput sample fractionation by tandem Equalizer
beads (EB) and Mercapto ethyl pyridine (MEP) beads was
used. We deposited 200 μl cyst fluid into each well of a 96-
well deep-well plates, and added 50 μl 2 M guanidine thio-
cyanate, 9 M urea 2% CHAPS, and 50 mM Tris-HCl pH 9.
After shaking for 20 minutes, each sample was diluted with
500 μl 50 mM Tris-HCl–containing protease inhibitor
cocktail (Roche, USA), and added to 70 μl 50% v/v
Equalizer resin bead (custom synthesized hexapeptide li-
braries, American Peptide, USA) in an FDTS-modified frit-
ted 96-well deep-well filter plate (Nunc, USA). The plate
was shaken for 60 minutes and centrifuged to collect the
unbound fraction. The whole unbound fraction was trans-
ferred to 200 μl 50% v/v MEP Hypercel bead (Pall Life
Sciences, USA) in an FDTS-modified fritted 96-well deep-
well filter plate (Nunc). The plate was shaken for 20 min-
utes and centrifuged to collect the flow-through fraction.Each well of the 96-well filter plate was washed with 500 μl
50 mM Tris-HCl 0.04% Triton X100 pH 7.5 four times.
Proteins bound to the Equalizer beads were differentially
eluted by (1) 100 μl 1 M NaCl, 50 mM Tris-HCl, 0.04%
Triton X100 pH 7.5 to yield fraction E1, (2) 100 μl 50% iso-
propanol/acetonitrile (2:1), 1% formic acid, 2% trifluoroace-
tic acid to yield fraction E2, (3) 100 μl 8 M guanidine-HCl,
1% Triton X100 (90°C) to yield fraction E3a, and (4) 100 μl
6 M urea, 30% ethylene glycol, 0.1 M sodium carbonate to
yield fraction E3b. Proteins bound to the MEP beads were
differentially eluted by (1) 150 μl 50% isopropanol/aceto-
nitrile (2:1), 0.5% formic acid, 1% trifluoroacetic acid to
yield fraction M1, (2) 150 μl 8 M guanidine-HCl, 1% Triton
X100 (90°C) to yield fraction M2a, and (3) 150 μl 6 M urea,
30% ethylene glycol, 0.1 M sodium carbonate to yield
fraction M2b. Finally, 20-40 μl aliquot of each eluted frac-
tion was added to 200 μl of buffer in a bioprocessor con-
taining either cation exchange ProteinChip array CM10
(Ciphergen, USA) or immobilized Cu ProteinChip array
IMAC30 (Ciphergen). After 45 minutes incubation the
arrays were washed with 200 μl buffer, then rinsed with
water. Sinapinic acid was added and the chip-bound pro-
teins were profiled with a PCS4000 mass spectrometer
(Ciphergen) with data acquisition up to 250 kDa m/z and a
matrix cutoff of 1 kDa. Each array was read twice and mass
focus was set at 4 kDa for first reading and 15 kDa for sec-
ond reading, sample rate was set at 400 and spectra were
collected by the accumulation of 540 shots in the positive
mode. Mass accuracy was calibrated externally using All-
in-One Peptide and All-in-One Protein Standards (Cipher-
gen). Spectral patterns were then compared across samples
to find discriminating masses or changes in peak inten-
sities. The obtained spectra were analyzed by Ciphergen
Express data manager software with Biomarker Wizard
and Biomarker Pattern software. Mass spectra were base-
line subtracted and normalized to total ion current inten-
sity. Peaks were detected using a signal-to noise ratio of 5,
valley depth of 5, 20% minimum peak threshold of all
spectra, and a mass range of 2-200 kDa. The peak clusters
were completed by a second mass peak detection using a
signal-to-noise ratio of 2, valley depth of 2 and cluster
mass window of 1 peak width. All analyses were blinded
to the operator.
Determination of marker identity
A couple of very prominent mass peaks characterize
SELDI/MALDI profiles of serum. These peaks primarily
represent highly abundant proteins like apolipoprotein
and fragments hereof. These abundant proteins can be
confidently identified based on mass matching with lit-
erature [20,27,39]. Each of the five peaks with ROC
AUC values >0.70 in our present study have been puri-
fied and identified in separate studies. The two members
of the apoplipoprotein family, ApoC-I and ApoC-III,
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The mass peak with m/z 6647 detected with MEP in
fraction M1 has been confidently identified as ApoC-I
[19-21,25,27] and the mass peak with m/z 9448 detected
with EB in fraction E3 has been confidently identified as
ApoC-III [19,20,25]. The mass peak with m/z 13900
detected with EB in fraction E3 has been confidently
identified as TTR [22,24,26], the mass peak with m/z
12886 detected with MEP in fraction M1 was identified
as SAA4 [21,26], and the mass peak with m/z 3902
detected with EB in fraction E3 has been identified as
PCI, also known as SerpinA5 [23].ELISA
Confirmation and validation samples were analyzed with
ApoC-III (Human) ELISA kit (KA0465, Abnova, Taiwan),
diluted 1:400 before analysis, and levels were presented
as μg/mL. PCI actibind ELISA kit (TC16100 Techno-
clone, Austria), samples were diluted 1:2 before analysis,
and levels were presented as percent of normal pooled
plasma. Both assays were run according to manufac-
turer’s instructions. For confirmation ovarian cystic fluid
samples from the original cohort were chosen based on
measured peak levels from the whole spectra of low to
high levels in the SELDI-TOF MS. For validation a new
set of 40 patient samples, consecutively collected to our
ovarian cyst fluid biobank (2008–2009), were included
(Table 3).Statistical analysis
Statistical analyses were performed in SPSS for Windows
(version 17), CiphergenExpress, and Prism 5.0 (Graph-
Pad). The Mann-Whitney U-test was used to identify
peaks with p-values <0.0001 for differences between be-
nign and epithelial ovarian tumors. The peak levels were
further subjected to logistic regression analysis to deter-
mine whether the cyst fluids could be classified. For each
model, ROC curves were constructed and values were
calculated for the AUCs. The relation between peak
levels and age was evaluated using bivariate Pearson cor-
relation coefficient and the relation between protein
levels measured with ELISA and SELDI-TOF MS was
evaluated with using bivariate Spearman correlation co-
efficient. Statistical differences in ELISA protein levels
between benign and malignant samples were evaluated
using the Mann-Whitney U test and a value of p <0.05
was considered to be significant.
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